OncoMed Pharmaceuticals Inc. (NASDAQ:OMED)’s share price traded up 3.5% on Monday . The stock traded as high as $10.65 and last traded at $10.52, with a volume of 198,763 shares changing hands. The stock had previously closed at $10.16.

Several equities analysts have recently weighed in on the company. Zacks Investment Research downgraded OncoMed Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 13th. Jefferies Group raised their price target on OncoMed Pharmaceuticals from $15.00 to $16.00 and gave the company a “buy” rating in a report on Wednesday, August 10th. Cantor Fitzgerald restated a “buy” rating and set a $16.00 price target on shares of OncoMed Pharmaceuticals in a report on Thursday, July 14th. Finally, Mizuho reduced their price target on OncoMed Pharmaceuticals from $45.00 to $40.00 and set a “neutral” rating for the company in a report on Wednesday, June 1st. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. OncoMed Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $19.29.

The firm’s market capitalization is $323.58 million. The company has a 50 day moving average of $12.17 and a 200-day moving average of $11.46.

OncoMed Pharmaceuticals (NASDAQ:OMED) last issued its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.91) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.81) by $0.10. The company earned $6.67 million during the quarter, compared to analysts’ expectations of $8.09 million. OncoMed Pharmaceuticals’s revenue was up 42.2% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.72) EPS. Analysts predict that OncoMed Pharmaceuticals Inc. will post ($3.39) earnings per share for the current fiscal year.

A hedge fund recently bought a new stake in OncoMed Pharmaceuticals stock. Jennison Associates LLC acquired a new position in OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 89,546 shares of the biopharmaceutical company’s stock, valued at approximately $2,018,000. Jennison Associates LLC owned approximately 0.30% of OncoMed Pharmaceuticals as of its most recent filing with the SEC.

OncoMed Pharmaceuticals, Inc (OncoMed) is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing anti-cancer stem cell (CSC) and immuno-oncology therapeutics. The Company’s product candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Anti-DLL4/VEGF Bispecific (OMP-305B83), Anti-RSPO3 (OMP-131R10) and GITRL-Fc.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.